Siegfried (SIX: SFZN), a global Contract Development and Manufacturing Organization (CDMO), announced the appointment of Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The move follows the company's decision to combine the COO roles for Drug Substances and Drug Products into a single position, supporting Siegfried's strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. He previously served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of around 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership positions at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks.
With his strong track record in integrated operations, Montanha will focus on further strengthening supply performance, operational efficiency and reliability across Siegfried's global network. Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He brings extensive international leadership experience, having lived and worked across Europe and Latin America.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, commented: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
The appointment aligns with Siegfried's strategy to provide integrated services from drug substances to drug products, as outlined in the company's recent announcements. For more information, visit the original release at newmediawire.com.
